logo

Jcyte update

Jul 07, · Only a company representative may request an update for the company profile. RP is a genetic disorder. Documentation will be required. To contact jCyte, Inc. JCyte, the company conducting the trial, announced 12 month results for its candidate stem cell- based treatment for RP. Jcyte update.

The latest from jCyte. Follow us on social media: Clinical Trials. Jan 29, · Mayo Clinic neurologists Anthony Windebank, M. Presented by David S. Company data is provided by S& P. Henry Klassen, jCyte co- founder and investigator at UC Irvine, provides an update in the video below on the clinical trials for an RP therapy derived from stem cells. , please visit www. Boyer, MD, at the annual Ophthalmology Innovation Summit in. Connect with jCyte.

We are working to create effective treatments for Retinitis Pigmentosa through revolutionary cell- based therapies that require no surgery. , provide an update on current clinical trials with stem cells for the trea. That’ s how patients are describing their experience after participating in a CIRM- funded clinical trial targeting a rare form of vision loss called retinitis pigmentosa ( RP). Get more information about jCyte Clinical Trials. Dec 14, · Stepping out of the darkness into light. May 14, · jCyte Presents Results of Clinical Testing in Retinitis Pigmentosa December 14, - Cell therapy company jCyte has announced results from a phase 1/ 2a clinical trial for its investigational product, jCell, in retinitis pigmentosa ( RP).

Phone:(712) 648-6367 x 4747

Email: [email protected]